title: Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy.
abstract: Adoptive cellular immunotherapy has proven to be a successful approach in preventing and curing cytomegalovirus infection and Epstein-Barr virus-associated lymphomas after bone marrow transplantation. Translation of this approach for preventing leukemia relapse after bone marrow transplantation might require ex vivo priming and long-term maintenance of leukemia blast-specific T cells. To accomplish this goal, procedures were optimized for the in vitro priming of naive CD8 using dendritic cells activated by CD40 ligation, interleukin-12 (IL-12), and IL-7. Using T lymphocytes and dendritic cells obtained from HLA-matched allogeneic bone marrow transplantation donors and leukemia blasts as a source of tumor antigens, anti-acute myeloid leukemia cytotoxic T lymphocytes (CTLs) were induced. In these experiments, it was found that though it is possible to induce CTLs using immature dendritic cells, IL-12, and IL-7, obtaining long-term CTLs requires the presence of CD4 T cells in the priming phase. Using this approach, long-term antileukemia CTL lines could be generated from 4 of 4 bone marrow donors. Because this procedure does not require definition of the target antigen and because it selects responding cells from a virgin T-cell repertoire, its general application is suggested in adoptive immunotherapy and in the definition of tumor rejection antigens.
authors.affiliation: BMT Laboratory and BMT Units, Department of Pediatrics, Laboratory of Organ Transplantation, IRCCS Policlinico San Matteo, University of Pavia, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Montagna
authors.forename: R
authors.initials: R
authors.lastname: Maccario
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: V
authors.initials: V
authors.lastname: Rosti
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.forename: P
authors.initials: P
authors.lastname: Farness
authors.forename: A
authors.initials: A
authors.lastname: Moretta
authors.forename: P
authors.initials: P
authors.lastname: Comoli
authors.forename: E
authors.initials: E
authors.lastname: Montini
authors.forename: A
authors.initials: A
authors.lastname: Vitiello
mesh_terms: D016026:Bone Marrow Transplantation / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D003713:Dendritic Cells / Q000276:immunology; D006680:HLA Antigens / Q000032:analysis; D006648:Histocompatibility; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D018664:Interleukin-12 / Q000494:pharmacology; D015851:Interleukin-7 / Q000494:pharmacology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D019013:CD40 Antigens; D006680:HLA Antigens; D015851:Interleukin-7; D018664:Interleukin-12